ABCL-041: Soluble MIC-A and MIC-B, and NKG2D Expression in NK Cells, NKT Cells, and Gamma-Delta T Lymphocytes in Patients with De Novo Non-Hodgkin Lymphoma and Post-Chemotherapy

Abstract

Context: The presence of soluble NKG2D receptor ligands in different types of cancer affects the cytotoxic functionality of NK cells by interfering with the receptor. Objective: Determine the levels of soluble MIC-A and MIC-B (sMICA, sMICB), the NKG2D receptor and the subpopulations of NK, NKT and Tγδ cells, in patients with de novo NHL and post-chemotherapy, and its relationship to treatment response. Design: Peripheral blood (SP) in EDTA from patients diagnosed with NHL was taken prior to the start of treatment and at least 3 months after chemotherapy. Healthy donors (SD) were included as controls. Setting: By flow cytometry using monoclonal antibodies lymphocyte subpopulations and NKG2D receptor expression were determined, and by ELISA, the levels of sMICA and sMICB. Patients or other participants: 50 patients with de novo NHL, indolent (N=17) and aggressive (N=33), from these 26 post-chemotherapy samples were obtained. Patients of both genders, over 18 years old, with informed consent, never treaty with chemotherapy and without contaminating viral disease. Interventions: There were not, only the sample taken described in setting. Main outcome measures: Before carrying out the project we hypothesized that the high levels of sMICA and sMICB in patients with NHL, as well as the low expression of the NKG2D receptor in SP of these patients are associated with poor response to treatment and poor prognosis in disease evolution. Results: Decrease (P Conclusions: The high level of sMIC in the serum of patients with NHL and the decrease of circulating dendritic, NK, helper (Th), and TCD4reg cells propose a possible mechanism for evasion of the antitumor response of NHL cells.